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Importance of the study 
This manuscript reports the evidence-based guidelines on management of ependymal tumors in 
children and adults developed by a multidisciplinary Task Force of the EANO, composed of 
medical experts from different European Countries representing the involved disciplines 
(neurology, neurosurgery, neuropathology, radiation oncology and pediatric oncology). These 
guidelines should aid all professionals involved in the management of patients with ependymal 
tumors in the daily clinical practice, and could also serve as a source of knowledge for institutions 
and insurance companies involved in cancer care in Europe.   
 
Keywords: Ependymoma, Molecular Pathology, Treatments, Children, Adults. 
 
Abstract 
Ependymal tumors are rare CNS tumors and may occur at any age but their proportion among 
primary brain tumors is highest in children and young adults.  Thus, the level of evidence of 
diagnostic and therapeutic interventions is higher in the pediatric compared with the adult patient 
population.  
The diagnosis and disease staging is performed by cranio-spinal magnetic resonance. Tumor 
classification is achieved by histological and molecular diagnostic assessment of tissue specimens 
according to the WHO classification 2016. Surgery is the crucial initial treatment in both children 
and adults. In pediatric patients with intracranial ependymomas of WHO grades II or III, surgery 
is followed by local radiotherapy regardless of residual tumor volume. In adults, radiotherapy is 
employed in patients with anaplastic ependymoma WHO grade III, and in case of incomplete 
resection of WHO grade II ependymoma. Chemotherapy alone is reserved for young children <12 
months and for adults with recurrent disease when further surgery and irradiation are no longer 
feasible. A gross total resection is the mainstay of treatment in spinal ependymomas, and 
radiotherapy is reserved for incompletely resected tumors. Nine subgroups of ependymal tumors 
across different anatomical compartments (supratentorial, posterior fossa, spinal) and patient ages 
have been identified with distinct genetic and epigenetic alterations, and with distinct outcomes. 
These findings  may lead to more precise diagnostic and prognostic assessments, molecular 
subgroup-adapted therapies, and eventually new recommendations pending validation in 
prospective studies. 
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Introduction 
Ependymal tumors are rare central nervous system tumors.1According to the Central Brain Tumor 
Registry of the United States of America (CBTRUS), the annual incidence of ependymal tumors 
is estimated at 0.43 patients per 100,000 population.2 These tumors account for 1.8 % of all 
primary central nervous system (CNS) tumors and for 6.8 % of all gliomas2. In children (0-
19 years of age) ependymal tumors are proportionally more common and account for 5.2 % of all 
primary CNS tumors.2 Overall, these tumors affect males more frequently than females (1.3:1).  
Ependymal tumors are of neuroectodermal origin and subdivided according to the World Health 
Organization (WHO) classification of CNS tumors into distinct entities and histological variants.3 
The WHO classification also comprises a histological grading into three distinct grades of 
malignancy, i.e. WHO grade I, II or III.  
In addition to age and tumor grade, the prognosis is associated with tumor location (supratentorial, 
infratentorial, and spinal) and site-specific molecular genetics.4-7 Population-based 
epidemiological data reported a 5-year overall survival rate of 83.4 % and a 10-year overall 
survival rate of 79.1 % in patients with ependymal tumors.2  
A recent molecular classification has distinguished nine subgroups of ependymal tumors, that 
appear to reflect more precisely than histology alone the biological, clinical and histopathological 
heterogeneity across the major anatomical compartments, age groups and tumor grades.6 Each of 
the nine molecular subgroups is characterized by distinct DNA methylation profiles and associated 
genetic alterations.  
Prospective studies on management of ependymoma patients have been performed in the pediatric 
population only, while smaller retrospective series are available for adult patients.8 In this 
Guideline we have separated the review of evidence concerning diagnosis and treatment 
recommendations for children and adults, recognizing that this is somewhat artefactual and may 
be replaced by molecular profiling-based stratification for treatment in the future. 
 
Methods  
The European Association of Neuro-Oncology (EANO) ependymoma Task Force assessed the 
available English literature until December 31 2016, sorted the scientific evidence into classes I–
IV, and rated recommendations at levels A–C according to the European Federation of the 
Neurological Societies Guidelines.9 When sufficient evidence for recommendations was not 
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available, the Task Force offered advice as a Good Practice Point. Specific recommendations for 
the therapeutic management of ependymomas in adults and children are reported in Tables 1-6.  
 
Clinical and neuroimaging diagnosis 
The clinical presentation of ependymomas (Supplementary Material) depends primarily on 
patient age, tumor location and tumor size.10-14.  
Magnetic resonance imaging (MRI) with contrast enhancement is the modality of choice for 
diagnosing ependymal tumors.15,16 Computed tomography (CT) can better depict calcifications, 
which are most commonly observed in subependymomas. Infratentorial ependymomas arise from 
the floor of the fourth ventricle while supratentorial ependymomas can be located in the brain 
rather than in the ventricles. Intracranial ependymomas commonly appear as well-circumscribed 
mass lesions, and have a heterogeneous appearance on T1-, T2- and post-contrast MRI, displaying 
varying degrees of contrast enhancement.  
Advanced imaging modalities may assist in diagnosis or management in some clinical scenarios; 
however, the available data from the literature are too scarce and do not allow for definitive 
recommendations for daily clinical practice. Diffusion-weighted imaging (DWI) may be useful for 
differentiating pilocytic astrocytomas, medulloblastomas, and ependymomas in the posterior 
fossa.17 MR spectroscopy (MRS) reveals elevated choline and reduced N-acetylaspartate (NAA) 
levels.8 Perfusion MRI may display elevated cerebral blood volume (CBV) values and have some  
prognostic value.18 Spinal cord ependymomas display more distinct borders than diffuse 
astrocytomas.14 Cyst formation and T2 hypointensity of the cyst wall due to blood products 
(‘hemosiderin cap’) are suggestive of ependymoma. An associated syringomyelia is common.  
Myxopapillary ependymoma is typically located in the conus medullaris, cauda equina and filum 
terminale region. 
 
 
 
Neuropathological diagnostics of ependymal tumors 
Ependymal tumors are classified according to the WHO classification of CNS tumors 2016.3 
Histological assessment is primarily based on hematoxylin-eosin-stained sections and some 
ancillary techniques, including silver impregnation for reticulin fibers, Alcian blue for 
demonstration of mucoid changes, and PAS staining for glycogen. Immunohistochemically, 
ependymal tumors react positive for glial fibrillary acidic protein (GFAP) and protein S100 but 
usually lack nuclear positivity for OLIG2. Dot-like perinuclear and ring-like cytoplasmic 
Rudà N-O-D-17-00425R1 
 
6 
 
immunoreactivity for epithelial membrane antigen (EMA) is a characteristic feature.19 Nuclear 
immunoreactivity for RELA and expression of L1CAM may help to identify RELA fusion-
positive ependymomas.20,21 However, molecular testing for C11orf95-RELA fusion by fluorescent 
in situ hybridization (FISH) or reverse-transcription PCR analysis is required for a firm diagnosis.3 
Loss of nuclear expression of trimethylated histon 3 lysine 27 (H3-K27me3) distinguishes a 
prognostically unfavorable group of posterior fossa ependymomas in children,22 largely 
corresponding to the posterior fossa ependymoma type A (see below).6,23 Proliferative activity is 
commonly assessed by Ki-67 immunostaining; however, definite cut-offs for grading have not 
been defined.  
The 2016 WHO classification of CNS tumors includes five distinct entities of ependymal tumors.3 
Myxopapillary ependymoma WHO grade I is histologically characterized by cuboidal or elongated 
tumor cells forming fibrillary processes towards fibrovascular cores typically showing 
perivascular mucoid degeneration. Mitotic activity is low. Subependymoma WHO grade I is 
characterized by clusters of bland to mildly pleomorphic, mitotically inactive cells embedded in 
an abundant fibrillary matrix with frequent microcystic changes and dystrophic calcifications. 
Ependymoma WHO grade II usually shows a solid, well-circumscribed growth and is composed 
of uniform cells forming perivascular pseudorosettes and, in some tumors, true ependymal 
rosettes. Mitotic activity is low while non-palisading necroses may be present in a fraction of cases. 
Three variants of ependymoma, each characterized by distinct histological features, are recognized 
in the WHO classification, namely papillary ependymoma, clear cell ependymoma and tanycytic 
ependymoma. Ependymoma, RELA fusion-positive is a novel supratentorial ependymoma entity 
that is defined by the presence of a C11orf95-RELA fusion.6,20 It may correspond to WHO grade 
II or III but patient outcome is worse compared to other types of supratentorial ependymomas.6 
Anaplastic ependymoma WHO grade III carries histological features of anaplasia, in particular 
high mitotic activity and microvascular proliferation. Pseudopalisading necrosis may also be 
observed. However, accurate histological distinction of WHO grade II and III ependymomas is 
challenging and its role in predicting survival has been disputed.24 Hence, WHO grading is 
inadequate to reliably predict the outcome in individual patients, and molecular subgrouping or 
single molecular markers may offer new perspectives for improved prognostic 
stratification.4,6,25,26,27  
 
Treatment of newly diagnosed intracranial ependymal tumors in adults 
Adult intracranial ependymomas are rare tumors, and WHO grade II tumors are more frequent 
than WHO grade III (anaplastic) counterparts .10  
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Surgery is considered the first and crucial step of standard treatment. In the majority of studies 
extent of resection has emerged as one of the most significant predictors of outcome.28-33 In a 
retrospective series of WHO grade II ependymomas in adults31 the 5- and 10- year OS rates were 
86.1 and 81%, respectively. Preoperative Karnofsky Performance Score (KPS), extent of resection 
and tumor location were independent prognostic factors for overall survival. In particular, gross 
total resection (GTR), defined as no residual disease on post-contrast T1 and T2-weight images on 
a 3-month post-operative MRI, and infratentorial location were associated with a longer OS. GTR 
and tumor location were also independent factors predicting progression-free survival (PFS). 
Conversely, incomplete resection has an increased risk of tumor recurrence and CSF 
dissemination. However, in posterior fossa tumors encasement of the cranial nerves and brainstem 
vasculature might limit resectability.34 In case of persistent hydrocephalus despite tumor resection, 
shunting or endoscopic ventriculostomy need to be performed.  
Concepts  regarding target volume for radiation therapy have evolved: in the past, patients with 
ependymoma often received craniospinal irradiation. However, numerous studies demonstrated 
the efficacy of local fields in the treatment of ependymoma, achieving good local control with low 
risk of spinal dissemination.35 In adults, there is agreement that post-operative radiotherapy should 
be included in the standard of care for patients with anaplastic ependymoma (WHO grade III) and 
for patients with ependymomas (WHO grade II) after an incomplete resection.29,36 Conversely, the 
role of postoperative radiotherapy in patients with ependymoma WHO grade II undergoing GTR 
remains controversial.37 In two large retrospective studies, including patients with intracranial 
WHO grade II ependymomas,31,38 no significant association of radiotherapy with PFS or OS was 
found. However, in the French study31 the subgroup of patients with incompletely resected tumors 
receiving postoperative radiotherapy had longer PFS and OS than those who did not. 
Intracranial subependymoma is a rare WHO grade I tumor. Long-term survival can be expected 
after surgical removal, although poorly defined borders  have been reported to be associated with 
a shorter PFS.39 Postoperative radiotherapy has been employed in few patients after subtotal or 
partial resection.  
Recommendations regarding treatment of intracranial ependymomas in adults are summarized in 
Table 1. 
 
Treatment of newly diagnosed intracranial ependymal tumors in children  
More than half of all pediatric ependymomas occur in children younger than 3 years,40 and about 
two thirds of tumors are located in the posterior fossa.32 
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Surgery and radiotherapy  are the mainstay of treatment for ependymomas in children41. Extent of 
resection is the most important prognostic factor, but the site of the lesions (e.g. posterior fossa 
tumors involving the ponto-cerebellar region) can limit surgery due to involvement of the lower 
cranial nerves and brainstem42: thus, an incomplete resection is frequent in these patients. OS is 
around 70% at 5 years in case of GTR, but it is much lower with incomplete resection.43-45 A 
second–look surgery is increasingly undertaken when the first resection has been incomplete.46-48  
The benefit of post-operative radiotherapy has been shown in terms of local control and survival 
rates in children with intracranial ependymomas45 An Italian Study44 reported on attempted GTR 
followed by post-operative radiotherapy, and showed a 7-year estimate of local control, event-free 
survival and OS of 83.7%, 69% and 81%, respectively. Data from the St Jude’s Children Hospital45 
showed improved local control, EFS and OS with 59.4 Gy in 1.8 Gy fractions with 3DRT without 
any apparent increase of late neurocognitive deficits. Therefore, postoperative radiotherapy with 
59.4 Gy (1.8 Gy/fraction) has been advocated45 for children older than 3 years, while for children 
as young as 18 months or children with altered neurological status, the doses can be lowered to 54 
Gy49: this can be true even for children between 12 and 18 months.  A recent retrospective study 
on 206 patients reported that the main pattern of relapse was within the radiation fields even at 
59.4 Gy.50 As local control remains the primary goal of treatment, the possibility to compensate 
for an incomplete surgery by applying an hypofractionated stereotactic boost in addition to 
conventional radiotherapy has been proposed.51 In an Italian prospective clinical trial, patients with 
residual disease after first surgery, who received a boost of 8 Gy in addition to radiation and 
chemotherapy, had a 5-year PFS rate higher than 58%52. A prospective study has shown that 
hyperfractionated radiotherapy is safe but provides no outcome benefit compared with standard 
fractionated regimens53. 
The toxicity of radiotherapy in younger children is of concern, and IMRT has been employed to 
limit late sequelae.44 Merchant and colleagues54 developed a model combining dose-volume data 
with clinical factors to predict IQ outcomes and concluded that the radiation dose remains the most 
clinically significant determinant of IQ outcomes and even low doses, such as <20 Gy, delivered 
to the supratentorial brain, have an impact on the IQ. Proton therapy could be an alternative to 
conventional photon radiotherapy.55 In this regard, the Massachusetts General Hospital group 
reported the outcome of 70 children with localized ependymomas treated with proton therapy:56 at 
a median follow up of 46 months, local control and survival were excellent, and the complication 
rate particularly low. Proton therapy may be useful for posterior fossa ependymoma,57 as it can 
spare the dose exposure to supratentorial compartments of the brain and auditory structures. 
Supratentorial ependymomas, which are often large tumors and occur in children over 10 years of 
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age, also could represent a good indication for protons therapy in order to reduce the 
neurocognitive impairment, and in this regard the preliminary data are encouraging.58 
However, recent studies 59-61 have suggested that brainstem toxicity, including radiation 
necrosis, with proton treatment can occur: thus, it has been recommended to limit the dose 
to the brainstem.  Another study reported more imaging changes in brainstem with protons 
than with photons. 62 The benefit and risks of proton therapy need to be confirmed with 
modern proton treatments and in prospective studies.63 A prospective study (NCT01288235) 
with protons therapy is ongoing in US. 
The role of chemotherapy in children remains unproven despite intensive investigation.64 As there 
is reluctance to deliver radiation to very young children, post-operative chemotherapy has been 
frequently proposed, while in older children chemotherapy is delivered as an adjunct to 
radiotherapy. Postoperative chemotherapy, using various combinations of etoposide, vincristine, 
cyclophosphamide, platinum derivatives, and high-dose methotrexate, showed a 40% to 50% 
response rate.44,65-67 The role of intensified schedules of chemotherapy was suggested in baby 
protocols,66 especially for supratentorial tumors.68 In contrast, the use of immediate post-operative 
high-dose conformal radiotherapy in children under the age of 3 years led to 7-year progression-
free survival rates of 77%,45 albeit long-term follow-up for toxicity on development is pending. 
Thus far, radiotherapy deferral strategies that use chemotherapy have been abandoned in most 
institutions for children  aged more than 12 months. 
Two randomized trials are currently comparing post irradiation chemotherapy to observation. 
Recommendations regarding treatment of intracranial ependymomas in children are summarized 
in Tables 2, 3 and 4. A summary of prospective studies on radiotherapy in pediatric patients with 
ependymoma can be found in the Supplementary material. 
 
Treatment of recurrent intracranial ependymal tumors in adults and children 
Standard salvage options for recurrent ependymomas have not been identified. However, re-
operation  as well as re-irradiation are increasingly employed. 
Re-operation has been shown to be associated with improved prognosis.69 Among children, who 
underwent re-operation, there was a 5-year EFS of 19% in case of GTR, of 14% in case of 
incomplete resection, and of 8% without repeat surgery.70 Re-irradiation is performed in adults as 
well as in children, using either a full course of fractionated irradiation 69,71 or hypo-fractionated 
stereotactic irradiation 72-76 or proton therapy,77 and can achieve durable responses.  
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The role of chemotherapy for treatment of recurrent ependymoma in adults remains unclear, and 
is considered only when local treatment options (surgery and radiotherapy) have been 
exhausted.78,79 
Similar to other gliomas, temozolomide has been used for the treatment of adult patients with 
ependymoma. Some case reports suggested that temozolomide alone or in combination is active 
against recurrent WHO grade II or III ependymoma.80-84 A retrospective study on 18 patients with 
recurrent WHO grade II and III intracranial ependymomas failing re-operation or re-irradiation or 
both suggested an activity of temozolomide in the standard schedule both in terms of response 
(22% CR + PR) and outcome (PFS 9.69 months and OS 30.55 months).85 Responses were observed 
in chemotherapy-naïve patients only, and in most cases were delayed in appearance. Conversely, 
in another retrospective study86 on patients with WHO grade II intracranial ependymomas 
refractory to first line chemotherapy with platinum compounds, temozolomide in the standard 
schedule had a more limited activity with a response rate of 4%, a PFS of 2 months and OS of 3 
months. An explanation of this difference could be that all patients of this cohort86 were heavily 
pretreated, while the majority of patients of the other cohort85 were chemo-naïve, thus, receiving 
TMZ in an earlier phase of the disease. Temozolomide has also been used in combination with 
lapatinib in a single arm phase II study in patients with recurrent intracranial and spinal 
ependymoma.87 Lapatinib targets the epidermal growth factor receptor (ErbB1) and the related 
family member HER-2/neu (ErbB2), which are expressed on the surface of ependymoma cells. 
Fifty patients were enrolled in this trial and the treatment was overall well tolerated. Median PFS 
was 45 weeks for patients with WHO grade II, and 25.3 weeks for patients with WHO grade III 
anaplastic ependymomas. Responses to treatment correlated with higher ErbB2 mRNA expression 
in the tumor tissue. The rather modest activity of temozolomide against ependymoma might be 
due to the lack of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation  in 
ependymoma cells;88,89 however, even when present, MGMT promoter methylation may not 
correlate with response to temozolomide.85 
A few studies on the administration of platinum-based regimens, using either cisplatin or 
carboplatin, have been published. A retrospective study, including pediatric as well as adult 
patients, indicated a superiority of platinum-based over nitrosourea-based regimens.90 Another 
retrospective series reported higher response rates in patients with progressive or recurrent 
ependymoma treated with cisplatin compared to non platinum regimens, but no difference in terms 
of PFS and OS was observed. 91 Other drugs and regimens were only used in single patients, such 
as tamoxifen and isotretinoin.92 The anti-angiogenic agent bevacizumab has been administered in 
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a small cohort of 8 patients with recurrent WHO grade II or III adult intracranial ependymoma 
with a median PFS of 6.4  months and OS of 9.4 months.93 
Phase II studies in children with relapsing ependymomas have reported a low response rate with 
either standard94 or high dose chemotherapy.95 Metronomic therapies have produced some long 
term-stabilizations.96 Responses have been reported with oral etoposide97 or temozolomide.98 
Bevacizumab, in association with either irinotecan99 or lapatinib,100 has proven disappointing. 
Targeted agents, such as erlotinib97 or sunitinib101, failed to show activity in unselected patient 
cohorts. 
Recommendations regarding treatment of recurrent ependymomas are summarized in Table 3. 
 
Treatment of ependymal tumors of the spinal cord  
Ependymal tumors of the spinal cord are more common in adults than in children.10 They include 
WHO grade I subependymoma and myxopapillary ependymoma, and WHO grade II and III 
(anaplastic) ependymoma. Spinal cord ependymomas have a better prognosis than spinal cord 
astrocytomas, but factors affecting prognosis have not been defined except for GTR. 102  Advances 
in microsurgical techniques have allowed en bloc GTR over piecemeal subtotal resection as 
standard of care for spinal cord ependymomas. In the majority of cases a GTR can be performed 
with good functional results. Since good functional outcome is related to small tumor size and 
good neurological status at the time of surgery, resection is considered at an early stage of the 
disease.103,104 When GTR is not feasible because of infiltration of spinal cord or nerves roots, 
postoperative local radiotherapy is commonly employed. A recent review of the literature on 348 
patients with WHO grade II and III spinal cord ependymomas, who underwent surgery with known 
extent of resection (GTR or STR), with or without postoperative radiotherapy, has been 
performed.105 After multivariate analysis,  extent of resection and tumor grade were independent 
prognostic factors for OS and PFS, and radiotherapy prolonged PFS in patients receiving subtotal 
resection: median PFS was 48 months in patients treated with STR alone and 96 months for 
patients with STR followed by radiotherapy. The optimal dose is still a matter of debate with 
studies suggesting  either better or equivalent results with doses > 50 Gy.105,106  
Regarding conventional chemotherapy a small study on 10 patients with recurrent intramedullary 
ependymoma has reported that continuous oral etoposide is well tolerated and may be active.107  
Bevacizumab can provide clinical benefit in some patients, although the changes on MRI do not 
meet the current criteria for radiological tumor response.108 
Recommendations regarding treatment of spinal cord ependymomas are summarized in Table 5.  
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Large retrospective series on myxopapillary ependymomas (MPE) have been performed, including 
a large multinstitutional series of 183 patients,109 that showed  a 10-year OS of 92.4% and a 5- and 
10-year PFS rates of 69.5% and 61.2%. MPE recurrence was local in 84% patients, and 
leptomeningeal spread was observed in 9.3% patients. Extent of resection was a major independent 
factor predicting local control, while younger age (<36 yrs) was a negative prognostic factor. 
However, the irregular shape, contact with surrounding nerve roots and production of a myxoid 
matrix, particularly in the filum terminale, can make GTR particularly challenging with risks of 
postoperative neurological disability. A strong correlation between capsular violation at surgery 
and recurrence has been found.110 An OS at 10 years exceeding 90% has been recently confirmed 
in a SEER analysis on 773 patients.111 Presacral MPE shows a worse outcome compared to MPE 
of the filum terminale/cauda equina region. 
Compared to patients treated with surgery alone, post-operative radiotherapy, especially with high 
doses (≥ 50 Gy), has been shown to increase the local control and PFS (10-year PFS from ˂40% 
to 70%)  with good tolerance and without substantial late toxicity.112,113 A small series on adult 
patients with spinal MPE  has shown that patients treated by GTR followed by adjuvant 
radiotherapy had a better local control than patients treated with GTR alone114: however, 
prospective confirmatory data are needed.  
MPE is very rare in children. Although patients frequently present with disseminated tumor and/or 
develop recurrent or progressive disease following treatments,115 the OS at 5 and 10 years in the 
SEER database is estimated at 97% and 95%, respectively.116  A recent series from Johns Hopkins 
Hospital117 indicated a significant reduction in local failure for patients receiving radiotherapy 
following STR or GTR. A smaller series118 also confirmed the good local control with surgery and 
radiotherapy compared to GTR alone. 
Recommendations on treatment of myxopapillary ependymomas are summarized in Table 6. 
 
 
 
New molecular subgroups: implications for management 
The aforementioned international molecular classification recognizes nine molecular 
subgroups of ependymal tumors, three in each anatomical compartment of CNS, i.e. spine (SP), 
posterior fossa (PF), and supratentorial region (ST).6 One of the subgroups within each 
compartment corresponds to WHO grade I subependymomas (SE), (SP-SE, PF-SE and ST-SE), 
occurs exclusively in adults, and shows favourable prognosis, while the two other molecular 
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subgroups within the spine predominantly correspond to the histological diagnoses of 
myxopapillary ependymoma (SP-MPE) and WHO grade II-III ependymoma (SP-EPN).6  
Two molecular types of ependymomas have been identified in the posterior fossa, termed PF-EPN-
A and PF-EPN-B (posterior fossa ependymoma group A and B). PF-EPN-A tumors occur 
predominantly in infants and young children, are often in a lateral location and difficult to resect 
completely, and are associated with a high recurrence rate.23 Conversely, PF-EPN-B tumors occur 
largely in adolescent and young adults and are associated with a more favorable prognosis. Data 
from a recent retrospective study on four independent non-overlapping cohorts  of posterior fossa 
ependymomas119 found that patients with either PF-EPN-A or PF-EPN-B tumors appeared to 
benefit from GTR, with the survival rates being particularly poor for subtotally resected PF-EPN-
A, even in association with radiation therapy. Moreover, a large subset of patients with PF-EPN-
B, who received a GTR, did not recur even without adjuvant radiotherapy. Based on these data, 
participants in a multidisciplinary international consensus conference120 agreed that for PF-EPN-
A tumors in patients older than 12 months of age maximal safe resection and focal radiotherapy 
should be defined as standard of care; furthermore, due to the challenging localization of tumors, 
patients would benefit from being treated in specialized centers by experienced neurosurgeons. 
Conversely, for patients with PF-EPN-B tumors undergoing GTR, a randomized clinical trial 
comparing observation versus standard focal radiotherapy could be launched.  
A number of supratentorial ependymomas are characterized by fusions between C110RF95 and 
the RELA gene (ST-EPN-RELA),6,20 and occur in both children and adults. Retrospective studies 
have suggested that these tumors are associated with a poor prognosis, extent of resection not 
being significantly associated with outcome. Thus, in this patient population postoperative 
radiotherapy seems to be recommended. Another molecular subgroup of supratentorial 
ependymomas harbors recurrent fusion with the oncogene YAP1 (St-EPN-YAP1), is enriched in 
the pediatric population, and shows a favorable prognosis.6,20 Gain of chromosome arm 1q occurs 
in a subset of PF-EPN-A, PF-EPN-B and ST-EPN-RELA tumors, and has been shown to be an 
independent negative prognostic factor. 26,121,122  
In conclusion, all these molecularly subtypes with distinct prognosis will hopefully benefit from 
distinct personalized therapies. 
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Response to reviewers' comments: 
 
Reviewer #1: we thank the reviewer for the suggestions 
1) INTRODUCTION. Ependymoma frequency in children seems not so low from available 
papers. This sentence need a quotation. 
We have inserted the reference and replaced the CBTRUS report of 2015 with that of 2016 
2) INTRODUCTION. "Ependymal tumors are of neuroectodermal origin and classified according 
to the World Health Organization (WHO) classification of CNS tumors into distinct entities and 
histological variants": please avoid repetition (classification and classified in the same 
sentence9 
We have removed the repetition 
 
3) INTRODUCTION. In the following sentence be consistent by using infratentorial instead of 
posterior fossa. 
We have replaced “posterior fossa” with “infratentorial” 
 
4) The part dedicated to clinical symptoms could be shorten and put in a table. 
We have moved the description of clinical symptoms as a table in the Supplemetary Material 
 
5) TREATMENT FOR CHILDREN. The second page of children treatment contains a sentence 
concerning the safety of proton therapy that needs to be less enthusiastic.  
We have modified the sentence accordingly, and inserted new references on the effects of proton 
therapy 
6) NEW MOLECULAR SUBGROUPS. Mitigate also the sentence about a PF-EPN-B tumor study 
substituting "should" with "could". 
We have replaced “should” with “could” 
7) NEW MOLECULAR SUBGROUPS. Be precise about RELA study and prognosis by 
specifying that these report are retrospective studies. 
We have specified that data regarding RELA subtype come from retrospective studies 
 
8)  REFERENCES. Kilday paper needs a number.    
Done 
 
9)  Table 4 needs amendment. Since one of the Authors in the SIOP responsible for ependymoma 
protocol, ask him to properly edit this table. SOME ASPECTS:  
All commas in the numbers must be substituted with fullstops. It is not true that the GTV is 
contrast enhancing lesions because many ependymomas do not have enhancement. This must be 
corrected in all the table. Not all ependymomas have contrast enhancement. Boost must be erogated 
to 3D identifiable residual disease. 
Table 4 has been modified. 
 
10) In table 5 there are some mistake in spaces. 
Done 
 
11) The supplementary table about radiotherapy in children is quite confusing. I propose to put only 
prospective trials since retrospective are a very bing number. Add also Neuro Oncol. 2016 
Oct;18(10):1451-60, already quoted in references and the last to be published and Int J Radiat Oncol 
Biol Phys. 2009 Aug 1;74(5):1536-42 
We have reported prospective studies only , and added the reference (Couter et al, 2009) that has 
been suggested 
 
 
Reviewer #3: we thank the reviewer for the kind comments. No changes requested. 
 
 
 
Reviewer #4: this is a well written review and a herculean effort involving physician from the 
multidisciplinary teams across different European countries to develop evidence-based clinical 
practice guidelines for diagnosis and treatment of children with ependymal tumors. No new data are 
presented. There is little discussion of recent molecular alterations that have been identified. 
We thank the reviewer for the comments. We agree that we did not present new data as the aim of 
the Guidelines was to review the evidence from the literature and draw recommendations. This is 
the reason also for the limited discussion of recent molecular alterations.  
 
Supplementary Material: Neurological symptoms and signs at presentation in ependymal tumors  
 
• Symptoms of raised intracranial pressure, such as headache, vomiting, and altered mental status, due an obstruction of the flow of 
cerebrospinal fluid (CSF), thus causing hydrocephalus.  
• Ataxia due to cerebellar compression, edema and, sometimes, infiltration 
• Vertigo and nausea from compression and infiltration of the lateral recess and inferior half of the 4th-ventricular floor. 
• Cranial neuropathies due to brainstem involvement   
• Focal neurological deficit and/or seizures in supratentorial tumors 
• Torticollis and cervicalgia due to a tumor extension through the foramen of Magendie and into the cervical spinal canal in infratentorial 
tumors of children 
• Central spinal cord syndrome with pain and/or sensory disturbances (often a “suspended sensory level”), in spinal ependymomas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary material : Summary of radiotherapy studies in pediatric patients with ependymoma 
 
 
 
 
Author, year Type of study 
Treatment 
Number of 
patients 
Efficacy 
RT 
Chemotherapy Overall survival Progression-free survival Photon Proton 
Timermann et al, 
2000 Prospective trial 
54Gy at primary site in 13 
pts, 1Gy/fr; 35.2Gy CSI 
(1.5Gy/fr)+20Gy boost 
(2.0Gy/fr) in 40 pts 
 + 53 pts 3-y: 75.6% (all) 
3-y: 59.7% (all) 
3-y: 83.3% (CR) 
3-y: 38.5% (R+) 
Massimino et al,  
2004 Prospective trial 
HFRT 70.4Gy, 1.1Gy/fr 
twice daily  
+ in case of residual 
tumour (17 pts) 63 pts 
5-y: 75% (all) 
5-y: 82% (CR) 
5-y: 61% (R+) 
5-y: 56% (all) 
5-y: 65% (CR) 
5-y: 35% (R+) 
Merchant et al, 
2009 Prospective trial 
59.4 Gy(131 pts), 
1.8Gy/fr/d; 54Gy  (22pts) 
kids<18 months with 
complete resection 
 + for35 pts 153 pts 
7-y: 81% 
5-y: 93% (CR) 
5-y: 52.4% (R+) 
7-y EFS: 69.1% 
7-y LC: 87.3% 
5-y EFS: 81.5% (CR) 
5-y EFS: 41% (R+) 
Conter et al, 
2009 
 
Prospective trial 
60 Gy after complete 
resection (CR) and 66 Gy 
after partial resection, 
delivered in two daily 
fractions of 1 Gy, 
according to the early 
postoperative imaging 
findings. 
 no 24 pts 5-y: 74.8%  
5-y: 54.2% 
 
Massimino et al, 
2016 Prospective trial 
59.4 Gy(131 pts), 
1.8Gy/fr/d; with and 
additional boost of 
2X4Gy if residue.   
 + for   all pts 160 pts 
5-y : 65.4 % 
5-y :58.1% 
(residue and 
boost) 
 
5-y : 81.1 % 
5-y : 68.7 % (residue 
and boost) 
 
Table 1. Key recommendations for the treatment of newly diagnosed intracranial WHO grade II and III 
ependymomas in adults. 
Class of Evidence Level of Recommendation 
Resection is recommended to obtain an histological diagnosis and should be a gross total resection whenever 
feasible. As the morbidity can be significant, detailed informed preoperative counseling by a surgeon experienced 
in performing such surgery is important. 
II B 
Postoperative MRI should be performed to evaluate the extent of resection.  n.a. Good Practice Point 
A second-look surgery should be considered when the result of the first resection has not been satisfactory. III C 
Because a risk of CSF dissemination exists for all patients with newly diagnosed ependymoma, disease staging, 
including both craniospinal MRI and CSF cytology, is mandatory following surgery (not earlier than 2-3 weeks). n.a. Good Practice Point 
Postoperative conformal radiotherapy with doses up to 60 Gy is recommended for patients with WHO grade III 
(anaplastic) ependymomas regardless of the extent of resection. 
II B 
Postoperative conformal radiotherapy with doses of 54-59.4 Gy is recommended for patients with WHO grade II 
ependymomas following incomplete resection. 
III C 
Craniospinal irradiation (CSI) of 36 Gy is recommended in case of CSF or spinal dissemination with a boost  up to 
45-54 Gy on focal lesions. 
IV Good Practice Point 
Because of the risk of asymptomatic and/or late relapses patients should be followed long term with contrast-
enhanced MRI. n.a. Good Practice Point 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 2. Key recommendations for the treatment of newly diagnosed intracranial WHO grade II and III 
ependymomas in children. 
Class of Evidence Level of Recommendation 
Resection is recommended to obtain an histological diagnosis and should be a gross total resection whenever feasible. 
As the morbidity can be significant, detailed informed preoperative counseling by a surgeon experienced in 
performing such surgery is important. 
II B 
Postoperative MRI should be performed to evaluate the extent of resection.  n.a. Good Practice Point 
A second-look surgery should be considered when residual tumor is demonstrated on postoperative MRI and gross 
total resection is a realistic goal. II B 
Because a risk of CSF dissemination exists for all patients with newly diagnosed ependymoma, a disease staging, 
including both craniospinal MRI and CSF cytology, is mandatory following surgery (not earlier than 2-3 weeks) n.a. Good Practice Point 
Postoperative conformal radiotherapy with doses up to 59.4 Gy is recommended in children older than 18 months. II B 
Postoperative conformal radiotherapy with doses of 54 Gy is recommended in children between 12 months and 18 
months or in older children with poor neurological status. 
II B 
Chemotherapy alone is an option in children less than 18 months old, while it is recommended in children aged  less 
than 12 months. 
III C 
Craniospinal irradiation (CSI) is recommended in case of CSF or spinal dissemination with a boost on focal lesions 
with doses adapted to patient age. 
IV Good Practice Point 
Because of the risk of asymptomatic and/or late relapses patients should be followed long term with an enhanced 
MRI. n.a. Good Practice Point 
Serial monitoring of cognitive and endocrine functions with specific batteries following radiotherapy is recommended 
whenever feasible. n.a. Good Practice Point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Key recommendations for the treatment of recurrent intracranial ependymomas in adults and 
children. 
Class of Evidence Level of Recommendation 
Re-operation and/or re-irradiation should be proposed whenever possible. However, if only incomplete resection was 
achievable due to functional restrictions at first surgery, the same limitations will be faced at re-operation: hence, in 
these cases the indication for another incomplete resection should be made cautiously. 
III C 
In patients with recurrent ependymomas, who are no longer eligible for local treatments, chemotherapy might be 
warranted, particularly in patients with a good performance status. 
III C 
In adults, either platinum compounds or temozolomide (based on a more favorable toxicity profile) should be 
considered. Options for participation in a clinical trial should be explored. 
IV Good Practice Point 
In children,  the choice of chemotherapeutic drugs depends on previous exposures. Options for participation in a 
clinical trial should be explored. n.a. Good Practice Point 
Table 4. Key recommendations regarding non-surgical treatment of WHO grade II and III ependymomas in children 
 
 
 
CT : Chemotherapy. VEC : Vincristine/Etoposide/ cyclophosphamide regimen. GTV: Growth tumor volume; CTV : clinical target volume. 
 CT indication CT regimen CT timing RT Indication RT timing 
GTV (defined 
with MRI) CTV 
Total dose  
(Gy) 
Dose/ 
fraction Gy Technique 
Localized 
tumor, age 
>18 months 
Debatable 
 
VEC 
 
+/_ Cisplatin 
Maintenance systematically Post-operatively 
tumour bed  and 
3D identifiable 
residual disease 
5-10 mm 
around GTV 
 
59.4 1.8 
3DCRT or IMRT 
or proton 
 
Localized 
tumor, age 
>18 months 
with visible 
residual 
tumor after 
surgery 
Recommended 
VEC 
 
+/_ Cisplatin 
+/- 
HD 
Methotrexate 
Post-
operatively 
Stereotactic 
additional boost 
recommended 
within a 
prospective 
clinical trial with 
residue after 
chemotherapy 
Post-
operatively 
and post-
chemother
apy 
tumour bed  and 
3D identifiable 
residual disease 
 59.4+8 4 
3DCRT or IMRT 
or proton 
 
Localized 
tumor, age 
12-18 
months 
Recommended Baby UK Maintenance To be discussed Post-operatively 
tumour bed  and 
3D identifiable 
residual disease 
 54 1.6 – 1.8  
Localized 
tumor, age 
<12 months 
Recommended Baby UK Post-operatively NO NO - - - -  
Metastatic 
tumor Debatable 
VEC 
+/_ Cisplatin Before RT Salvage treatment 
Post-
operatively 
or post-
chemother
apy 
tumours and 3D 
identifiable 
residual disease 
CSI + boost 
5-10 mm 
around GTV 
24 or 36 
depending on age 
+ Boost up to 59 
1.8  
Local relapse None outside clinical  trial -  -  Recommended 
Post-
operatively 
3D identifiable 
disease GTV+2 mm 
59  or in a 
prospective trial 
25Gy/5 fractions 
or   24 Gy/ 3 
fractions 
1.8 or hypo- 
fractionation 
( 5 – 8) 
3DCRT or IMRT 
or proton or 
hypofractionated 
stereotactic 
irradiation 
Table 5. Key recommendations for the treatment of WHO grade II and III spinal cord ependymomas 
. 
Class of Evidence Level of Recommendation 
Gross total resection is the goal of spinal ependymoma surgery. II B 
Post-operative MRI should be performed to evaluate the extent of resection. n.a. Good Practice Point 
Because a risk of CSF dissemination exists for all patients with newly diagnosed ependymoma, disease 
staging, including both craniospinal MRI and CSF cytology, is recommended following surgery (not earlier 
than 2-3 weeks). 
n.a. Good Practice Point  
In case of WHO grade III (anaplastic) ependymomas, postoperative radiotherapy with doses of 45-54Gy is 
recommended regardless of the extent of resection. 
III C 
In case of WHO grade II ependymomas following gross total resection a watch-and-wait strategy is 
recommended. 
III C 
In case of incomplete resection of a WHO grade II ependymoma postoperative local radiotherapy is 
recommended with doses of 45-54 Gy.  
II B 
Because of the risk of asymptomatic and/or late relapses patients should be followed long term with an 
enhanced MRI. 
n.a. Good Practice Point 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Key recommendations for the treatment of myxopapillary ependymomas (MPE) WHO grade 
I. 
Class of Evidence Level of Recommendation 
Gross total resection is recommended whenever feasible. II B 
Postoperative MRI should be performed to evaluate the extent of resection.  n.a. Good Practice Point 
Because a risk of CSF dissemination exists for all newly diagnosed patients, disease staging, including both 
craniospinal MRI and CSF cytology, is recommended following surgery (not earlier than 2-3 weeks). n.a. Good Practice Point 
Post-operative radiotherapy with doses ≥50 Gy is recommended in case of incomplete resection.  
II B 
In case of relapse, re-operation, re-irradiation and chemotherapy should be considered. III C 
Because of the risk of asymptomatic and/or late relapses patients should be followed long term with an 
enhanced MRI. n.a. Good Practice Point 
 
